VBI VACCINES INC (VBIV)
CA91822J2020 - Common Stock
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
VBI Vaccines stock is up on Tuesday as shares of VBIV continue to be volatile after the company filed for bankruptcy last week.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We have all of the biggest pre-market stock movers that traders are going to want to read about on Tuesday!
VBI Vaccines Provides an Update on its Restructuring Proceedings
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
VBI Vaccines Announces Results of Annual General Meeting
VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024
VBIV stock results show that VBI Vaccines missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips VBI Vaccines (NASDAQ:VBIV) just reported results for the first quarter of 2024....
VBI Vaccines Reports First Quarter 2024 Financial Results
VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023
VBIV stock results show that VBI Vaccines beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
VBI Vaccines Reports Full Year 2023 Financial Results
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to dive into all of the biggest pre-market stock movers that traders will want to keep an eye on Friday morning!
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational...
VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences
Biopharmaceutical firm VBI Vaccines rose over 7% in premarket trading as Brii Biosciences announced the acquisition of VBI's HBV immunotherapeutic...
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain...
VBI Vaccines Reports Third Quarter 2023 Financial Results
